Seroepidemiological survey and study of cellular immunity against SARS-CoV2 in immunocompromised patients
Latest Information Update: 23 Dec 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 07 Dec 2022 Status changed from active, no longer recruiting to completed.
- 14 Oct 2021 New trial record
- 11 Oct 2021 Status changed from recruiting to active, no longer recruiting.